Metabasis names new vice president of intellectual property

Dr Holman was formerly at Amylin Pharmaceuticals from 2001 to 2007, most recently as executive director of intellectual property. While at Amylin, she led the group responsible for all corporate intellectual property matters, including patents, trademarks, copyrights, transactions and due diligence.

At Metabasis, Dr Holman will manage the company’s intellectual property portfolio covering its proprietary platform technologies and pipeline of product candidates on a worldwide basis, as well as support business development activities, provide legal support for transactions, negotiations, competitive analysis and due diligence, and manage other general corporate legal matters for the company.

Mark Erion, chief scientific officer and executive vice president of R&D, said: “Molly’s experience and background in the biotechnology and pharmaceutical arenas will be a valuable addition to our company and we are very excited that she has joined our team.”